Table 3.
Subgroup analysis based on race in patients treated with CDK4/6is plus ET.
| White | Black | Hispanic | ||||
|---|---|---|---|---|---|---|
| IDC, n = 1375 | ILC, n = 269 | IDC, n = 165 | ILC, n = 17 | IDC, n = 147 | ILC, n = 34 | |
| mPFS | 10.7 | 11.9 | 11.7 | 7.5 | 8.9 | 10.1 |
|
P = 0.125 HR 1.15 95% CI [0.96–1.35] |
P = 0.309 HR 0.74 95% CI [0.39–1.40] |
P = 0.813 HR 1.06 95% CI [0.63–1.77] |
||||
| mOS | 30.8 | 26.5 | 28.1 | 16.0 | 24.3 | 35.4 |
|
P = 0.115 HR 1.35 95% CI [0.85–1.36] |
P = 0.160 HR 0.53 95% CI [0.24–1.16] |
P = 0.194 HR 1.49 95% CI [0.86–2.88] |
||||
CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, mPFS median progression-free survival, mOS median overall survival, HR hazard ratio, CI confidence interval.